PMID- 35662613
OWN - NLM
STAT- MEDLINE
DCOM- 20220817
LR  - 20220817
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 189
DP  - 2022 Jul
TI  - Serum OPG/TRAIL ratio predicts the presence of cardiovascular disease in people 
      with type 2 diabetes mellitus.
PG  - 109936
LID - S0168-8227(22)00750-1 [pii]
LID - 10.1016/j.diabres.2022.109936 [doi]
AB  - AIMS: Cardiovascular disease (CVD) is the leading cause of mortality in type 2 
      diabetes mellitus (T2DM). Epidemiological studies suggest serum Osteoprotegrin 
      (OPG)/Tumour-necrosis-factor-related-apoptosis-inducing- ligand (TRAIL) ratio may 
      be a useful marker of cardiovascular risk. This study aimed to compare serum 
      levels of TRAIL, OPG and OPG/TRAIL ratio in people with T2DM, with and without a 
      history of CVD, and controls; and to determine which of these indices, if any, 
      predict cardiovascular risk. METHODS: In this single centre observational study 
      of 133 participants, people with T2DM, with and without a history of a 
      cardiovascular event in the last 5 years, were recruited along with a control 
      cohort without T2DM or CVD. Demographic information and anthropometric 
      measurements were recorded. Blood samples were taken and OPG and TRAIL were 
      measured using ELISA. RESULTS: People with T2DM and CVD had higher OPG/TRAIL 
      ratios compared to controls or those with a new diagnosis of T2DM. After 
      adjustment for potential confounding factors, OPG/TRAIL ratio was significantly 
      associated with the presence of CVD in people with T2DM and an OPG/TRAIL ratio 
      cut-off > 38.6 predicted the presence of CVD in this cohort with a sensitivity of 
      80% and specificity of 82%. CONCLUSION: This study suggests that OPG/TRAIL ratio 
      may have a role as a biomarker of CVD in people with T2DM.
CI  - Copyright (c) 2022 Elsevier B.V. All rights reserved.
FAU - Forde, H
AU  - Forde H
AD  - Department of Endocrinology, Beaumont Hospital and RCSI Medical School, Beaumont, 
      Dublin 9, Ireland; School of Biotechnology, Dublin City University, Glasnevin, 
      Dublin 9, Ireland. Electronic address: hannahforde@gmail.com.
FAU - Davenport, C
AU  - Davenport C
AD  - Department of Endocrinology, Beaumont Hospital and RCSI Medical School, Beaumont, 
      Dublin 9, Ireland; School of Biotechnology, Dublin City University, Glasnevin, 
      Dublin 9, Ireland.
FAU - Rochfort, K D
AU  - Rochfort KD
AD  - School of Nursing, Psychotherapy, and Community Health, Dublin City University, 
      Glasnevin, Dublin 9, Ireland.
FAU - Wallace, R G
AU  - Wallace RG
AD  - School of Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.
FAU - Durkan, E
AU  - Durkan E
AD  - School of Health and Human Performance, Dublin City University, Glasnevin, Dublin 
      9, Ireland.
FAU - Agha, A
AU  - Agha A
AD  - Department of Endocrinology, Beaumont Hospital and RCSI Medical School, Beaumont, 
      Dublin 9, Ireland.
FAU - Thompson, C J
AU  - Thompson CJ
AD  - Department of Endocrinology, Beaumont Hospital and RCSI Medical School, Beaumont, 
      Dublin 9, Ireland.
FAU - Tormey, W T
AU  - Tormey WT
AD  - Department of Chemical Pathology, Beaumont Hospital, Beaumont, Dublin 9, Ireland.
FAU - O'Gorman, D J
AU  - O'Gorman DJ
AD  - School of Health and Human Performance, Dublin City University, Glasnevin, Dublin 
      9, Ireland; National Institute for Cellular Biotechnology, Dublin City 
      University, Glasnevin, Dublin 9, Ireland.
FAU - Cummins, P M
AU  - Cummins PM
AD  - School of Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.
FAU - Smith, D
AU  - Smith D
AD  - Department of Endocrinology, Beaumont Hospital and RCSI Medical School, Beaumont, 
      Dublin 9, Ireland.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20220602
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Biomarkers)
RN  - 0 (Osteoprotegerin)
RN  - 0 (TNF-Related Apoptosis-Inducing Ligand)
SB  - IM
MH  - Biomarkers
MH  - *Cardiovascular Diseases/diagnosis/etiology
MH  - *Diabetes Mellitus, Type 2/complications
MH  - Humans
MH  - Osteoprotegerin
MH  - TNF-Related Apoptosis-Inducing Ligand
OTO - NOTNLM
OT  - Biomarker
OT  - Cardiovascular disease
OT  - Osteoprotegrin
OT  - Tumour-necrosis-factor-related apoptosis-inducing-ligand
EDAT- 2022/06/07 06:00
MHDA- 2022/08/18 06:00
CRDT- 2022/06/06 13:41
PHST- 2021/11/25 00:00 [received]
PHST- 2022/04/28 00:00 [revised]
PHST- 2022/05/30 00:00 [accepted]
PHST- 2022/06/07 06:00 [pubmed]
PHST- 2022/08/18 06:00 [medline]
PHST- 2022/06/06 13:41 [entrez]
AID - S0168-8227(22)00750-1 [pii]
AID - 10.1016/j.diabres.2022.109936 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2022 Jul;189:109936. doi: 10.1016/j.diabres.2022.109936. 
      Epub 2022 Jun 2.